EBMT 2024 | Promising novel agents in AML: menin inhibitors
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, briefly discusses promising novel agents being explored in acute myeloid leukemia (AML), highlighting the promise of menin inhibitors. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
I think, without doubt, anybody in AML is most excited about menin inhibitors. They clearly work. They’re clearly going to receive regulatory approval, and there’s about a half a dozen that are already marching along in that direction. So we’re going to rapidly, I think, have lots of choices. And they’re going to make a huge impact because they’re going to be useful in potentially the largest subset that we’ve yet seen of AML...
I think, without doubt, anybody in AML is most excited about menin inhibitors. They clearly work. They’re clearly going to receive regulatory approval, and there’s about a half a dozen that are already marching along in that direction. So we’re going to rapidly, I think, have lots of choices. And they’re going to make a huge impact because they’re going to be useful in potentially the largest subset that we’ve yet seen of AML. And you say, well, MLL is very rare because the KMT2A rearrangement is rare, it’s true, but it looks like it’s active in NPM1-mutated AML, which is a huge subset of AML. And when we learn the approval part as a monotherapy is just the first step, it’s when we incorporate it into the standard regimens and combine it with our other targeted agents that it’s really going to make a huge impact. I think, five years from now, the field’s going to be totally on its head with how we’re treating the disease with that new inhibitor.
Read more...
Disclosures
Consultant: Astellas, Daiichi Sankyo, Novartis.
